Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 5, 2015, Pages 582-590

  Verna, E C ^a   Patel, J ^b   Bettencourt, R ^c   Nguyen, P ^b,c   Hernandez, C ^b,c   Valasek, M A ^c   Kisselva, T ^b   Brenner, D A ^b   Loomba, R ^b,c  

^a Columbia University College of Physicians and Srgens ^*  (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PENTRAXIN; PENTRAXIN 2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PLASMA PROTEIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ELASTOGRAPHY; FEMALE; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; RECEIVER OPERATING CHARACTERISTIC; STAGING; AGED; BLOOD; COMPLICATION; LIVER CIRRHOSIS; METABOLISM; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; BIOMARKERS; BLOOD PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84938547622     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13292     Document Type: Article

References (43)

1. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
2. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V,. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40: 1209-22.
3. Maharjan AS, Roife D, Brazill D, Gomer RH,. Serum amyloid P inhibits granulocyte adhesion. Fibrogenesis Tissue Repair 2013; 6: 2.
4. Cox N, Pilling D, Gomer RH,. Distinct Fcgamma receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibrocyte differentiation. J Immunol 2014; 193: 1701-8.
5. Castano AP, Lin SL, Surowy T, et al,. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009; 1: 5ra13.
6. Crawford JR, Pilling D, Gomer RH,. FcgammaRI mediates serum amyloid P inhibition of fibrocyte differentiation. J Leukoc Biol 2012; 92: 699-711.
7. Haudek SB, Trial J, Xia Y, Gupta D, Pilling D, Entman ML,. Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci USA 2008; 105: 10179-84.
8. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD,. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 2008; 456: 989-92.
9. Bharadwaj D, Mold C, Markham E, Du Clos TW,. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol 2001; 166: 6735-41.
10. Mold C, Gresham HD, Du Clos TW,. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol 2001; 166: 1200-5.
11. Naik-Mathuria B, Pilling D, Crawford JR, et al,. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen 2008; 16: 266-73.
12. Murray LA, Chen Q, Kramer MS, et al,. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 2011; 43: 154-62.
13. Dillingh MR, van den Blink B, Moerland M, et al,. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther 2013; 26: 672-6.
14. Cong M, Jiang C, Taura K, et al,. Serum Amyloid P Attenuates Hepatic Fibrosis in Mice by Inhibiting the Activation of Fibrocytes and Hepatic Stellate Cells. Hepatology 2011; 54 (4 Suppl.): 736A.
15. Available at: www.clinicaltrials.gov (accessed 8 March 2015).
16. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
17. Noureddin M, Lam J, Peterson MR, et al,. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58: 1930-40.
18. Le TA, Chen J, Changchien C, et al,. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-32.
19. Permutt Z, Le TA, Peterson MR, et al,. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-9.
20. Tang A, Tan J, Sun M, et al,. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013; 267: 422-31.
21. Patel NS, Doycheva I, Peterson MR, et al,. Effect of weight loss on MRI estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015; 13: 561-8.
22. Patel NS, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R,. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 37: 630-9.
23. Loomba R, Wolfson T, Ang B, et al,. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60: 1920-8.
24. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL,. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013; 268: 411-9.
25. Cui J, Ang B, Haufe W, et al,. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 2015; 41: 1271-80.
26. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL,. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56.
27. Yin M, Talwalkar JA, Glaser KJ, et al,. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-13 e2.
28. Xanthakos SA, Podberesky DJ, Serai SD, et al,. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr 2014; 164: 186-8.
29. Venkatesh SK, Yin M, Ehman RL,. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 2013; 37: 544-55.
30. Alberti L, Gilardini L, Zulian A, et al,. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009; 202: 455-60.
31. Barazzoni R, Aleksova A, Carriere C, et al,. Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome. Cardiovasc Diabetol 2013; 12: 167.
32. Witasp A, Ryden M, Carrero JJ, et al,. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS ONE 2013; 8: e63493.
33. Miyaki A, Choi Y, Maeda S,. Pentraxin 3 production in the adipose tissue and the skeletal muscle in diabetic-obese mice. Am J Med Sci 2014; 347: 228-33.
34. Miyamoto T, Rashid Qureshi A, Heimburger O, et al,. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol 2011; 6: 2785-91.
35. Osorio-Conles O, Guitart M, Chacon MR, et al,. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab 2011; 301: E1254-61.
36. Abderrahim-Ferkoune A, Bezy O, Chiellini C, et al,. Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. J Lipid Res 2003; 44: 994-1000.
37. Miyaki A, Maeda S, Choi Y, Akazawa N, Eto M, Tanaka K, et al,. Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals. Am J Hypertens 2013; 26: 1250-5.
38. Kim J, Gozal D, Bhattacharjee R, Kheirandish-Gozal L,. TREM-1 and pentraxin-3 plasma levels and their association with obstructive sleep apnea, obesity, and endothelial function in children. Sleep 2013; 36: 923-31.
39. Du Clos TW,. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm 2013; 2013: 379040.
40. Pilling D, Roife D, Wang M, et al,. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007; 179: 4035-44.
41. Murray LA, Rosada R, Moreira AP, et al,. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE 2010; 5: e9683.
42. Santhiago MR, Singh V, Barbosa FL, Agrawal V, Wilson SE,. Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits. Exp Eye Res 2011; 93: 786-9.
43. Murray LA, Kramer MS, Hesson DP, et al,. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair 2010; 3: 11.